Drug Search Results
More Filters [+]

Mipsagargin

Alternative Names: mipsagargin, g-202
Latest Update: 2022-10-13
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Rebus
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mipsagargin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Renal Cell Carcinoma|Glioblastoma|Prostate Cancer|Hepatocellular Carcinoma

Phase 1: Skin Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

G-202-008

P2

Withdrawn

Glioblastoma

2019-10-01

G-202-006

P2

Completed

Renal Cell Carcinoma

2016-12-01

G-202-005

P2

Completed

Prostate Cancer

2016-12-01

G-202-004

P2

Completed

Glioblastoma

2016-12-01

Recent News Events